Related Experiment Video
Updated: May 22, 2025
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.5K
Practical implementation of automated insulin delivery systems in 2025: A French position statement update
E Bismuth1, M Joubert2, E Renard3
1Endocrinologie et Diabétologie pédiatrique, Hôpital Robert Debré, APHP Nord, Université de Paris, Paris, France.
Diabetes & Metabolism
|March 12, 2025
Summary
Automated insulin delivery (AID) systems significantly improve type 1 diabetes management for diverse populations. Updated French guidelines expand AID accessibility and refine follow-up for optimal glycemic control and safety.
Area of Science:
- Endocrinology
- Diabetology
- Medical Technology
Background:
- Automated insulin delivery (AID) systems revolutionized type 1 diabetes management since 2020.
- Real-world data and research advancements necessitate guideline updates for broader AID accessibility and optimized patient care.
Purpose of the Study:
- To update the French consensus on AID systems, expanding indications and refining guidelines.
- To optimize patient follow-up and ensure safe, effective AID implementation for diverse populations.
Main Methods:
- Review of real-world data and recent research findings.
- Analysis of benefits and safety in specific patient populations.
- Development of updated guidelines for healthcare professionals and patients.
Main Results:
- AID systems consistently improve glycemic control (reduced HbA1c, increased time-in-range, minimized hypoglycemia).
- Benefits are evident in special populations including children, pregnant women, and those with insulin resistance.
- Safe transitions from multiple daily injections to AID are demonstrated.
Conclusions:
- Updated guidelines support broader AID indications for special populations, emphasizing personalized system selection.
- Multidisciplinary education, telemonitoring, and individualized follow-up are crucial for AID efficacy and safety.
- Future research explores fully automated systems, adjunctive therapies, and AID application in type 2 diabetes.
Related Concept Videos
01:27Insulin Formulations: Types and Delivery
150
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
150
01:25Insulin: Biosynthesis, Chemistry, and Preparation
332
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
332
01:16Insulin: Dosing Regimen and Adverse Effects
135
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
135
01:15Diabetes: Management and Pharmacotherapy
220
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
220
01:24Glucagon-like Receptor Agonists
281
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
281